Biological effects of MC2050, a quinazoline-based PARP-1 inhibitor, in human neuroblastoma and EBV-positive Burkitt's lymphoma cells

ChemMedChem. 2011 Apr 4;6(4):606-11. doi: 10.1002/cmdc.201000536. Epub 2011 Mar 1.

Authors

Luciana Mosca¹, Dante Rotili, Italo Tempera, Alessandra Masci, Mario Fontana, Roberta Chiaraluce, Paola Mastromarino, Maria d'Erme, Antonello Mai

Affiliation

¹ Department of Biochemical Sciences, "Sapienza" University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy. luciana.mosca@uniroma1.it

PMID: 21365766
DOI: 10.1002/cmdc.201000536

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Burkitt Lymphoma / metabolism
Burkitt Lymphoma / pathology
Dose-Response Relationship, Drug
Enzyme Inhibitors / chemical synthesis
Enzyme Inhibitors / chemistry
Enzyme Inhibitors / pharmacology*
Herpesvirus 4, Human / drug effects*
Herpesvirus 4, Human / growth & development
Herpesvirus 4, Human / metabolism
Humans
Neuroblastoma / metabolism
Neuroblastoma / pathology
Poly(ADP-ribose) Polymerase Inhibitors*
Quinazolines / chemical synthesis
Quinazolines / chemistry
Quinazolines / pharmacology*
Tumor Cells, Cultured

Substances

Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Quinazolines